---
document_datetime: 2025-12-02 05:36:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/levitra.html
document_name: levitra.html
version: success
processing_time: 0.1156667
conversion_datetime: 2025-12-28 09:03:59.231232
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Levitra

[RSS](/en/individual-human-medicine.xml/66468)

##### Authorised

This medicine is authorised for use in the European Union

vardenafil Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Levitra](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Levitra. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levitra.

Expand section

Collapse section

## What is Levitra?

Levitra is a medicine that contains the active substance vardenafil. It is available as film-coated tablets (5, 10 and 20 mg) and as orodispersible tablets (10 mg). Orodispersible tablets are tablets that dissolve in the mouth.

## What is Levitra used for?

Levitra is used to treat adult men (aged 18 years or over) with erectile dysfunction (sometimes called impotence), when they cannot get or keep a hard penis (erection) sufficient for satisfactory sexual activity. For Levitra to be effective, sexual stimulation is required.

The medicine can only be obtained with a prescription.

## How is Levitra used?

The recommended dose of Levitra is 10 mg, taken about 25 to 60 minutes before sexual activity. The orodispersible tablets must be taken without liquid. If Levitra film-coated tablets are taken with a high-fat meal, the onset of activity may be delayed. The dose of the film-coated tablets may be increased to a maximum of 20 mg or decreased to 5 mg, depending on the effectiveness of treatment and any side effects.

A starting dose of 5 mg should be considered for patients with mild and moderate liver problems or severe kidney problems. The dose may need to be adjusted in patients taking other medicines that block enzymes that break down Levitra. For full details, see the package leaflet.

The maximum recommended dosing frequency is one film-coated tablet or orodispersible tablet per day.

## How does Levitra work?

The active ingredient of Levitra, vardenafil, belongs to a group of medicines called phosphodiesterase-type-5 (PDE5) inhibitors. It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP). During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax. This allows blood to flow into the corpora, producing the erection. By blocking the breakdown of cGMP, Levitra restores erectile function. Sexual stimulation is still needed to produce an erection.

## How has Levitra been studied?

Levitra tablets were compared with placebo (a dummy treatment) in four main studies including a total of 2,431 men with erectile dysfunction aged 20 to 83 years. One of these studies was carried out in diabetic men and another in men who had had their prostate gland removed. Two additional main studies compared orodispersible tablets with placebo in 701 men aged 21 to 84 years

In all of the studies, the main measure of effectiveness was the ability to get and maintain an erection. This was recorded in two questionnaires completed at home. The studies lasted 12 weeks.

## What benefit has Levitra shown during the studies?

Levitra tablets and orodispersible tablets were significantly more effective than placebo for all measures in all of the studies.

## What is the risk associated with Levitra?

The most common side effect with Levitra (seen in more than 1 patient in 10) is headache. For the full list of all side effects reported with Levitra, see the package leaflet.

Levitra must not be used in people who are hypersensitive (allergic) to vardenafil or any of the other ingredients. It must not be used when sexual activity is inadvisable, such as in men with severe heart disease. It must also not be used in patients who have ever had loss of vision because of a problem with blood flow to the nerve in the eye (non?arteritic anterior ischemic optic neuropathy or NAION). Levitra must not be taken with nitrates (medicines used to treat angina).

Because Levitra has not been studied in the following group patients, they must not use the medicine:

- patients with severe liver disease or end-stage kidney disease requiring dialysis;
- patients who have hypotension (low blood pressure);
- patients who have had a stroke or a heart attack within the last six months;
- patients with unstable angina and hereditary eye problems known as 'retinal degenerative disorders'.

Levitra must not be taken with ketoconazole and itraconazole (used to treat fungal infections) in men over 75 years of age, or with medicines called 'HIV protease inhibitors' such as ritonavir or indinavir (used to treat HIV infection).

In addition, Levitra must not be taken with medicines known as guanylate cyclase stimulators, including riociguat (used to treat pulmonary hypertension [high blood pressure in the lungs]).

## Why has Levitra been approved?

The CHMP decided that Levitra's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Levitra?

A risk management plan has been developed to ensure that Levitra is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Levitra, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Levitra

The European Commission granted a marketing authorisation valid throughout the European Union for Levitra on 6 March 2003.

For more information about treatment with Levitra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Levitra : EPAR - Summary for the public

English (EN) (87.99 KB - PDF)

**First published:** 25/08/2009

**Last updated:** 29/03/2016

[View](/en/documents/overview/levitra-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-996)

български (BG) (116.48 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/bg/documents/overview/levitra-epar-summary-public_bg.pdf)

español (ES) (87.71 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/es/documents/overview/levitra-epar-summary-public_es.pdf)

čeština (CS) (115.1 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/cs/documents/overview/levitra-epar-summary-public_cs.pdf)

dansk (DA) (87.54 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/da/documents/overview/levitra-epar-summary-public_da.pdf)

Deutsch (DE) (89.54 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/de/documents/overview/levitra-epar-summary-public_de.pdf)

eesti keel (ET) (86.61 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/et/documents/overview/levitra-epar-summary-public_et.pdf)

ελληνικά (EL) (118.1 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/el/documents/overview/levitra-epar-summary-public_el.pdf)

français (FR) (88.22 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/fr/documents/overview/levitra-epar-summary-public_fr.pdf)

hrvatski (HR) (109.81 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/hr/documents/overview/levitra-epar-summary-public_hr.pdf)

italiano (IT) (86.93 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/it/documents/overview/levitra-epar-summary-public_it.pdf)

latviešu valoda (LV) (112 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/lv/documents/overview/levitra-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (112.12 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/lt/documents/overview/levitra-epar-summary-public_lt.pdf)

magyar (HU) (110.05 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/hu/documents/overview/levitra-epar-summary-public_hu.pdf)

Malti (MT) (116.7 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/mt/documents/overview/levitra-epar-summary-public_mt.pdf)

Nederlands (NL) (88.88 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/nl/documents/overview/levitra-epar-summary-public_nl.pdf)

polski (PL) (114.58 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/pl/documents/overview/levitra-epar-summary-public_pl.pdf)

português (PT) (88.26 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/pt/documents/overview/levitra-epar-summary-public_pt.pdf)

română (RO) (111.78 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/ro/documents/overview/levitra-epar-summary-public_ro.pdf)

slovenčina (SK) (114.32 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/sk/documents/overview/levitra-epar-summary-public_sk.pdf)

slovenščina (SL) (107.39 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/sl/documents/overview/levitra-epar-summary-public_sl.pdf)

Suomi (FI) (93.16 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/fi/documents/overview/levitra-epar-summary-public_fi.pdf)

svenska (SV) (87.13 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

29/03/2016

[View](/sv/documents/overview/levitra-epar-summary-public_sv.pdf)

Levitra : EPAR - Risk-management-plan summary

English (EN) (58.42 KB - PDF)

**First published:** 27/06/2019

[View](/en/documents/rmp-summary/levitra-epar-risk-management-plan-summary_en.pdf)

## Product information

Levitra : EPAR - Product Information

English (EN) (762.04 KB - PDF)

**First published:** 25/08/2009

**Last updated:** 20/01/2025

[View](/en/documents/product-information/levitra-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-552)

български (BG) (850.46 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/bg/documents/product-information/levitra-epar-product-information_bg.pdf)

español (ES) (778.75 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/es/documents/product-information/levitra-epar-product-information_es.pdf)

čeština (CS) (829.63 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/cs/documents/product-information/levitra-epar-product-information_cs.pdf)

dansk (DA) (774.21 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/da/documents/product-information/levitra-epar-product-information_da.pdf)

Deutsch (DE) (832.56 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/de/documents/product-information/levitra-epar-product-information_de.pdf)

eesti keel (ET) (808.58 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/et/documents/product-information/levitra-epar-product-information_et.pdf)

ελληνικά (EL) (899.08 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/el/documents/product-information/levitra-epar-product-information_el.pdf)

français (FR) (866.33 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/fr/documents/product-information/levitra-epar-product-information_fr.pdf)

hrvatski (HR) (816.25 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/hr/documents/product-information/levitra-epar-product-information_hr.pdf)

íslenska (IS) (761.97 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/is/documents/product-information/levitra-epar-product-information_is.pdf)

italiano (IT) (843.63 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/it/documents/product-information/levitra-epar-product-information_it.pdf)

latviešu valoda (LV) (799.64 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/lv/documents/product-information/levitra-epar-product-information_lv.pdf)

lietuvių kalba (LT) (781.39 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/lt/documents/product-information/levitra-epar-product-information_lt.pdf)

magyar (HU) (814.54 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/hu/documents/product-information/levitra-epar-product-information_hu.pdf)

Malti (MT) (908.7 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/mt/documents/product-information/levitra-epar-product-information_mt.pdf)

Nederlands (NL) (787.91 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/nl/documents/product-information/levitra-epar-product-information_nl.pdf)

norsk (NO) (785.11 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/no/documents/product-information/levitra-epar-product-information_no.pdf)

polski (PL) (848.4 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/pl/documents/product-information/levitra-epar-product-information_pl.pdf)

português (PT) (738.21 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/pt/documents/product-information/levitra-epar-product-information_pt.pdf)

română (RO) (807.73 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/ro/documents/product-information/levitra-epar-product-information_ro.pdf)

slovenčina (SK) (843.49 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/sk/documents/product-information/levitra-epar-product-information_sk.pdf)

slovenščina (SL) (839.81 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/sl/documents/product-information/levitra-epar-product-information_sl.pdf)

Suomi (FI) (838.7 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/fi/documents/product-information/levitra-epar-product-information_fi.pdf)

svenska (SV) (775.07 KB - PDF)

**First published:**

25/08/2009

**Last updated:**

20/01/2025

[View](/sv/documents/product-information/levitra-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00003098/202403 13/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Levitra : EPAR - All Authorised presentations

English (EN) (28.62 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 15/09/2016

[View](/en/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-955)

български (BG) (60.31 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/bg/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_bg.pdf)

español (ES) (29.8 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/es/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_es.pdf)

čeština (CS) (41.64 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/cs/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (30.96 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/da/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (28.01 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/de/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (31.93 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/et/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (57.36 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/el/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_el.pdf)

français (FR) (30.08 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/fr/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (60.96 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/hr/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (29.53 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/is/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_is.pdf)

italiano (IT) (28.32 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/it/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (57.46 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/lv/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (65.83 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/lt/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (57.58 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/hu/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.74 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/mt/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (29.66 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/nl/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (29.84 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/no/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_no.pdf)

polski (PL) (58.14 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/pl/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_pl.pdf)

português (PT) (29.66 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/pt/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.7 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/ro/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.07 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/sk/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (39.8 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/sl/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.13 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/fi/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (31.05 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/09/2016

[View](/sv/documents/all-authorised-presentations/levitra-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Levitra Active substance vardenafil International non-proprietary name (INN) or common name vardenafil Therapeutic area (MeSH) Erectile Dysfunction Anatomical therapeutic chemical (ATC) code G04BE09

### Pharmacotherapeutic group

Urologicals

### Therapeutic indication

Treatment of erectile dysfunction in adult men.

Erectile dysfunction is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

In order for Levitra to be effective, sexual stimulation is required.

Levitra is not indicated for use by women.

## Authorisation details

EMA product number EMEA/H/C/000475 Marketing authorisation holder

Bayer AG

51368 Leverkusen Germany

Marketing authorisation issued 06/03/2003 Revision 34

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Levitra : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (158.44 KB - PDF)

**First published:** 25/08/2009

**Last updated:** 20/01/2025

[View](/en/documents/procedural-steps-after/levitra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Levitra-H-C-PSUSA-00003098-202403 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/19518/2025

English (EN) (92.81 KB - PDF)

**First published:** 20/01/2025

[View](/en/documents/scientific-conclusion/levitra-h-c-psusa-00003098-202403-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Levitra-H-C-PSUSA-00003098/201903 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/684494/2019

English (EN) (117.06 KB - PDF)

**First published:** 20/12/2019

[View](/en/documents/scientific-conclusion/levitra-h-c-psusa-00003098201903-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Levitra-H-C-475-X-28 : EPAR - Assessment Report - Extension

Adopted

English (EN) (528.59 KB - PDF)

**First published:** 24/09/2010

**Last updated:** 24/09/2010

[View](/en/documents/variation-report/levitra-h-c-475-x-28-epar-assessment-report-extension_en.pdf)

## Initial marketing authorisation documents

Levitra : EPAR - Scientific Discussion

English (EN) (244.21 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/levitra-epar-scientific-discussion_en.pdf)

Levitra : EPAR - Procedural steps taken before authorisation

English (EN) (89.29 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/levitra-epar-procedural-steps-taken-authorisation_en.pdf)

#### More information on Levitra

- [Observational Study Description H6D-MC-LVHQ(b) A Prospective Case-Crossover Study to Evaluate the Possible Association Between the Use of PDE5 inhibitors and the Risk of Acute Nonarteritic Anterior Ischaemic Optic Neuropathy (NAION) - post-authorisation study](https://catalogues.ema.europa.eu/study/18651)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/01/2025

## Share this page

[Back to top](#main-content)